Shoichiro Mukai

Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma

Hironori Betsunoh, Shoichiro Mukai, Yutaka Akiyama et al. · Cancer Science · 2007 · 84 citations · Full text

Activation of hepatocyte growth factor activator zymogen (pro‐HGFA) by human kallikrein 1‐related peptidases

Shoichiro Mukai, Tsuyoshi Fukushima, Daiji Naka et al. · FEBS Journal · 2008 · 61 citations · Full text

Human Growth, Pathology, Dextran Sulfate +17

Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis

Shoichiro Mukai, Kenji Yorita, Yukari Kawagoe et al. · Human Cell · 2014 · 45 citations · Full text

Urology, Oncology, Matriptase Expression +15

Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR

Takashi Kobayashi, Katsuhiro Ito, Takahiro Kojima et al. · Cancer Immunology Immunotherapy · 2021 · 37 citations · Full text

Urology, Second-line Pembrolizumab Treatment, Genitourinary Cancer +7

Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression.

Satoru Sugie, Shoichiro Mukai, Koji Yamasaki et al. · PubMed · 2015 · 32 citations

Urology, Genitourinary Cancer, Plasma Levels +13